GALAPAGOS NV/S (GLPG) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of GALAPAGOS NV/S (NASDAQ:GLPG) from a hold rating to a buy rating in a research report sent to investors on Tuesday. They currently have $109.00 price target on the biotechnology company’s stock.
According to Zacks, “Galapagos NV is a biotechnology company. The Company’s operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. “
A number of other research analysts also recently weighed in on GLPG. ValuEngine downgraded GALAPAGOS NV/S from a strong-buy rating to a buy rating in a report on Wednesday, January 2nd. Cantor Fitzgerald assumed coverage on GALAPAGOS NV/S in a report on Wednesday, December 19th. They set an overweight rating and a $130.00 price target on the stock. BidaskClub upgraded GALAPAGOS NV/S from a sell rating to a hold rating in a report on Tuesday, September 18th. Credit Suisse Group upgraded GALAPAGOS NV/S from a neutral rating to an outperform rating in a report on Thursday, December 13th. Finally, Raymond James assumed coverage on GALAPAGOS NV/S in a research note on Wednesday, November 14th. They issued a strong-buy rating and a $157.00 target price on the stock. Two research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $122.00.
GALAPAGOS NV/S (NASDAQ:GLPG) last issued its quarterly earnings results on Friday, October 26th. The biotechnology company reported $0.33 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.70. GALAPAGOS NV/S had a negative return on equity of 7.66% and a negative net margin of 30.65%. The business had revenue of $119.99 million for the quarter, compared to the consensus estimate of $82.15 million. On average, analysts anticipate that GALAPAGOS NV/S will post -1.74 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Federated Investors Inc. PA boosted its stake in shares of GALAPAGOS NV/S by 17.8% during the 3rd quarter. Federated Investors Inc. PA now owns 1,677,922 shares of the biotechnology company’s stock worth $188,648,000 after acquiring an additional 253,159 shares in the last quarter. Laurion Capital Management LP bought a new stake in shares of GALAPAGOS NV/S during the 3rd quarter worth about $19,841,000. Marshall Wace LLP bought a new stake in shares of GALAPAGOS NV/S during the 3rd quarter worth about $15,319,000. Jane Street Group LLC boosted its stake in shares of GALAPAGOS NV/S by 214.1% during the 3rd quarter. Jane Street Group LLC now owns 185,269 shares of the biotechnology company’s stock worth $20,830,000 after acquiring an additional 126,277 shares in the last quarter. Finally, Aquilo Capital Management LLC bought a new stake in shares of GALAPAGOS NV/S during the 2nd quarter worth about $6,088,000. Hedge funds and other institutional investors own 18.13% of the company’s stock.
About GALAPAGOS NV/S
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Further Reading: What is the Quick Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.